Dasatinib and Quercetin to Treat Fibrotic Non-alcoholic Fatty Liver Disease

NCT05506488 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

NAFLD
NASH With Fibrosis
Liver Fibrosis

Interventions

DRUG: Dasatinib 100 MG + Quercetin (1000 MG)
OTHER: Placebo

Sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)